Skip to main
ANAB
ANAB logo

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio Inc is positioned positively due to its ongoing development of immune cell modulating antibodies, including two key assets—rosnilimab and ANB032—in clinical-stage trials targeting significant autoimmune and inflammatory diseases. The promising efficacy data reported for rosnilimab in mitigating gastrointestinal symptoms indicates a favorable risk/reward profile, especially in relation to upcoming data for its use in ulcerative colitis and the protection provided by ongoing Jemperli royalties. Furthermore, the company's valuation appears robust with updated projections for royalties contributing to an increased price target, reflecting positive expectations for its future financial health.

Bears say

AnaptysBio Inc faces significant challenges that may adversely impact its stock performance, primarily due to the inherent risks associated with its clinical-stage development programs. Concerns surrounding potential safety signals, suboptimal efficacy in clinical trials, and increasing commercial competition could hinder the approval and market success of key product candidates like rosnilimab and Jemperli. Furthermore, if sales projections for these products fail to materialize due to intense market competition or reimbursement issues, the company's financial outlook may be further compromised, causing broader implications for investor confidence.

AnaptysBio (ANAB) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 9 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.